ALNYLAM PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Operating Activities in USD from Q1 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from Q1 2010 to Q1 2025.
  • Alnylam Pharmaceuticals, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2025 was -$118M, a 45.1% decline year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was -$8.31M, a 108% decline from 2023.
  • Alnylam Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was $104M.
  • Alnylam Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$541M, a 15.6% increase from 2021.
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Growth (%)

ALNYLAM PHARMACEUTICALS, INC. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$118M -$36.8M -45.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q1 2024 -$81.5M +$85M +51% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q1 2023 -$166M +$4.72M +2.76% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q1 2022 -$171M +$64.5M +27.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q1 2021 -$236M +$10.5M +4.27% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q1 2020 -$246M -$57.7M -30.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q1 2019 -$189M -$32.8M -21.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q1 2018 -$156M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q1 2013 -$971K +$29.2M +96.8% Jan 1, 2013 Mar 31, 2013 10-Q 2013-05-07
Q1 2012 -$30.2M -$23.9M -379% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-07
Q1 2011 -$6.31M +$9.3M +59.6% Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-03
Q1 2010 -$15.6M Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-05

ALNYLAM PHARMACEUTICALS, INC. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$8.31M -$112M -108% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-13
2023 $104M +$645M Jan 1, 2023 Dec 31, 2023 10-K 2025-02-13
2022 -$541M +$100M +15.6% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-13
2021 -$642M -$26.7M -4.35% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 -$615M -$337M -121% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 -$278M +$284M +50.5% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-10
2018 -$563M -$180M -47% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-11
2017 -$383M -$75.1M -24.4% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-13
2016 -$308M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-14
2013 -$68.7M +$47M +40.6% Jan 1, 2013 Dec 31, 2013 10-K 2014-02-20
2012 -$116M -$28.5M -32.8% Jan 1, 2012 Dec 31, 2012 10-K 2014-02-20
2011 -$87.1M -$2.73M -3.23% Jan 1, 2011 Dec 31, 2011 10-K 2014-02-20
2010 -$84.3M Jan 1, 2010 Dec 31, 2010 10-K 2013-02-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.